Study suggests benefits may be long lasting Following a ketogenic diet for six months significantly reduced measures of body fat and fatigue, eased disease symptoms, and improved exercise capacity, cognition, and arm and hand dexterity in people with relapsing-remitting multiple sclerosis (RRMS), a study has shown. The research, Ketogenic diet in relapsing multiple sclerosis: Patient perceptions, post-trial…
Category: Multiple Sclerosis
Positive CHMP opinion for multiple sclerosis biosimilar natalizumab
July 24, 2023 — Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for marketing authorisation for first-of-a-kind biosimilar natalizumab developed by Polpharma Biologics. The authorisation covers treatment as a single disease-modifying…
Subcutaneous Ocrevus injection – OCARINA II trial results
Phase III trial results could strengthen Ocrevus’s position in multiple sclerosis GlobalData, 19th July 2023: Genentech recently announced positive results from its phase III trial, OCARINA II (NCT05232825), investigating the efficacy of Ocrevus (ocrelizumab) as a subcutaneous injection, administered twice yearly for ten minutes, in patients diagnosed with relapsing multiple sclerosis (RMS) and primary progressive…
AI award for Queen Mary University of London and icometrix
Queen Mary and icometrix have together been awarded the prestigious AI Award in Health and Care by the National Institute for Health and Care Research (NIHR) 7th March 2023 The collaborative programme will investigate the impact of AI on the assessment of MRI and decision making for people with multiple sclerosis (MS). It is hoped…
Primary Progressive MS confirmed to be distinct from other MS subtypes
Long suspected by the research community, new study from Tisch MS Research Center of New York, published in Brain, finally establishes that PPMS is pathophysiologically separate from other forms of MS Findings have groundbreaking implications for targeted treatment of PPMS, a disease characterised by worsening neurological function and progressive disability in patients The Tisch MS…
Tecfidera lowers risk of first MS symptoms in RIS
Treatment with Tecfidera (dimethyl fumarate) significantly reduces the risk of experiencing the first multiple sclerosis (MS) symptoms in adults with radiologically isolated syndrome (RIS), according to data from a Phase 4 clinical trial which may lead to changes in practice. RIS is a condition in which patients have MS-like lesions on MRI scans, but lack typical symptoms of the disease. This…
EMD Serono highlights new data for Evobrutinib
First BTKi to demonstrate sustained clinical benefit for people with RMS through three and a half years of treatment Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining low in people with RMS after three and a half years of therapy…
Preserving cognitive function in RRMS
Bristol Myers Squibb presents new data showing effect of early Zeposia (ozanimod) treatment in improving and preserving cognitive function in people with Relapsing Multiple Sclerosis. On June 24th, Bristol Myers Squibb presented results of the DAYBREAK open-label extension trial at the 8th European Academy of Neurology Congress in Vienna, Austria. New post-hoc analyses from the Zeposia (ozanimod) Phase 3…
Aubagio study: no disease activity after 2 years
More than half (58% )of the people with multiple sclerosis (MS) treated with Aubagio (teriflunomide) showed no evidence of disease activity after two years on treatment, according to an Italian study. The study, “Evolution of teriflunomide use in multiple sclerosis: A real-world experience,” was published in the Journal of the Neurological Sciences. Aubagio is an oral disease-modifying therapy that has been…
